{
    "data": [
        {
            "id": "180093",
            "type": "article",
            "attributes": {
                "publishOn": "2009-12-29T04:08:56-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Setback for Gilead's Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/180093-setback-for-gileads-pipeline"
            }
        },
        {
            "id": "178280",
            "type": "article",
            "attributes": {
                "publishOn": "2009-12-15T13:15:30-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Little to Show After Cardiovascular Push",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/178280-gilead-little-to-show-after-cardiovascular-push"
            }
        },
        {
            "id": "177888",
            "type": "article",
            "attributes": {
                "publishOn": "2009-12-13T02:16:06-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Closer to FDA Approval for CF Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/177888-gilead-closer-to-fda-approval-for-cf-drug"
            }
        },
        {
            "id": "167928",
            "type": "article",
            "attributes": {
                "publishOn": "2009-10-21T15:00:16-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Is in Great Health",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21435",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/167928-gilead-sciences-is-in-great-health"
            }
        },
        {
            "id": "160871",
            "type": "article",
            "attributes": {
                "publishOn": "2009-09-10T12:33:55-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Taking Profits from Swine Flu with Tamiflu",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21435",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "88518",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/160871-taking-profits-from-swine-flu-with-tamiflu"
            }
        },
        {
            "id": "159973",
            "type": "article",
            "attributes": {
                "publishOn": "2009-09-04T05:43:43-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Expect Share Price to Move Up",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20422",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "88479",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/159973-gilead-sciences-expect-share-price-to-move-up"
            }
        },
        {
            "id": "158522",
            "type": "article",
            "attributes": {
                "publishOn": "2009-08-27T04:24:50-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "YM BioSciences Is Loaded with Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23051",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/158522-ym-biosciences-is-loaded-with-potential"
            }
        },
        {
            "id": "154864",
            "type": "article",
            "attributes": {
                "publishOn": "2009-08-09T03:48:01-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "YM BioSciences: Trading Below Cash with Multiple Catalysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20831",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/154864-ym-biosciences-trading-below-cash-with-multiple-catalysts"
            }
        },
        {
            "id": "141892",
            "type": "article",
            "attributes": {
                "publishOn": "2009-06-08T04:41:46-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Looks Good on Strong Sales and Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "87743",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/141892-gilead-looks-good-on-strong-sales-and-pipeline"
            }
        },
        {
            "id": "136147",
            "type": "article",
            "attributes": {
                "publishOn": "2009-05-07T11:44:46-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Profitable Viral Marketing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21652",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/136147-gilead-sciences-profitable-viral-marketing"
            }
        },
        {
            "id": "132599",
            "type": "article",
            "attributes": {
                "publishOn": "2009-04-23T08:04:08-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: A Biotech No More",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22462",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/132599-gilead-sciences-a-biotech-no-more"
            }
        },
        {
            "id": "117857",
            "type": "article",
            "attributes": {
                "publishOn": "2009-02-02T03:57:01-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Great Quarter, Strong Anti-Viral Franchise Make It a Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "87061",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/117857-gilead-sciences-great-quarter-strong-anti-viral-franchise-make-it-a-buy"
            }
        }
    ]
}